Insights Into Chronic Lymphocytic Leukemia (CLL) Northeast

Perspectives of community physicians from the northeast region of the United States on the management of newly diagnosed and relapsed/refractory chronic lymphocytic leukemia (CLL)

Northeast – August 25, 2020

Faculty Chair

Javier Pinilla, MD, PhD

Moffitt Cancer Center, Tampa, FL, US

Example Report

Start discovering the insights

View Report


Report providing the insights from a moderated roundtable discussion focusing on treatment of CLL
Disease state and data presentations were developed in conjunction with Dr Javier Pinilla from Moffitt Cancer Center

Insights on the following CLL therapies were obtained:

  • acalabrutinib,  ibrutinib, zanubrutinib, obinutuzumab, rituximab, venetoclax, duvelisib, idelalisib, FCR, BR

Data collection was accomplished through use of audience response system questioning and in-depth moderated discussion


The group of advisors comprised community oncologists from the northeast region of the United States

Purchase Report

Thank you for your interest in our insights.

Complete the form below to receive additional information.